EPROBEMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H19ClN2O2
Molecular Weight	282.766
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C(C=C1)C(=O)NCCCN2CCOCC2

InChI

InChIKey=YYFGRAGNYHYWEZ-UHFFFAOYSA-N

InChI=1S/C14H19ClN2O2/c15-13-4-2-12(3-5-13)14(18)16-6-1-7-17-8-10-19-11-9-17/h2-5H,1,6-11H2,(H,16,18)

HIDE SMILES / InChI

Molecular Formula	C14H19ClN2O2
Molecular Weight	282.766
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2054504 | http://www.provizor-online.ru/2013/01/befol_befolum

Eprobemide (brand name Befol/Бефол), a drug used in Russia, is a selective, reversible monoamine oxidase A (MAO) inhibitor, which causes deamination of noradrenaline, serotonin, partially dopamine and β-phenylethylamine, thus increases the content of neurotransmitter monoamines in the central nervous system. Befol does not affect the deaminination of the tyramine and does not cause its accumulation in the body, in contrast to non-selective inhibitors of irreversible action, that is why the drug causes fewer side effects. Befol is used in adults with depression of different nature: endogenous depression in manic-depressive psychosis and various forms of schizophrenia, depression in patients with chronic alcoholism.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Amine oxidase [flavin-containing] A 14 Target ID: P21397 Gene ID: 4128.0 Gene Symbol: MAOA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2054504	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depressive disorder 179 Sources: http://www.provizor-online.ru/2013/01/befol_befolum	Primary		Approved 8583	befol Approved Use Unknown
Manic-depressive disease 9 Sources: http://www.provizor-online.ru/2013/01/befol_befolum	Primary		Approved 8583	befol Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 429 CYP1A2 2153	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65659#section=Biological-Test-Results Page: 45.0	inconclusive
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65659#section=Biological-Test-Results Page: 100.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65659#section=Biological-Test-Results Page: 90.0	no
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65659#section=Biological-Test-Results Page: 90.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65659#section=Biological-Test-Results Page: 3.0	yes [IC50 2.1876 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65659#section=Biological-Test-Results Page: 88 \| 90	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/65659#section=Biological-Test-Results Page: 28.0

PubMed

Title	Date	PubMed
[Anti-arrhythmia activity of befol, sufan, mexidol, and T3-146 in combination with other anti-arrhythmia agents].	1998-05	9644555
[Effect of befol and sufan on the neurogenic atrial fibrillation].	1998-04	9631721
[Mechanism of action of befol on calcium metabolism in cardiomyocytes using the fluorescent probe fura-2].	1996-03	8688530
[New pharmacodynamic effects of gidazepam and befol in patients with cardiac arrhythmias].	1993-09-01	7906171
[The action of befol and its derivatives on monoamine oxidase of different origins].	1991-03	2054504
[A comparative study of befol pharmacokinetics in experimental animals and man].	1990-03-01	2369959

Patents

Sample Use Guides

In Vivo Use Guide

Oral or intravenously or intramuscularly. Oral: 2 times a day 30-50 mg (up to 100-150 mg). The daily dose is up to 400 mg. To avoid disturbance of sleep, the second dose should be no later than 18 hours. For prolonged and resistant depressions, treatment begins with intravenous administration of the drug (40-60 drops per minute) or spray (for 1-2 minutes). With intramuscular administration of befol, single doses may be 10-25 mg, daily intake 20-50 mg.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:43:24 GMT 2025` Edited by `admin` on `Wed Apr 02 09:43:24 GMT 2025`
Record UNII	URX5F7RDER
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

P-CHLORO-N-(3-MORPHOLINOPROPYL)BENZAMIDE

Preferred Name

English

EPROBEMIDE

Official Name

English

eprobemide [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C265